PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-3502.85
Negative P/E while Drug Manufacturers - Specialty & Generic median is 5.74. Seth Klarman would scrutinize path to profitability versus peers.
No Data
No Data available this quarter, please select a different quarter.
666.69
P/B exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.79. Jim Chanos would check for potential asset write-down risks.
-16985.44
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is 0.00. Seth Klarman would investigate cash flow improvement potential.
-16985.44
Negative operating cash flow while Drug Manufacturers - Specialty & Generic median P/OCF is 0.00. Seth Klarman would investigate operational improvement potential.
666.69
Fair value ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.80. Jim Chanos would check for valuation bubble risks.
-0.01%
Negative earnings while Drug Manufacturers - Specialty & Generic median yield is 0.24%. Seth Klarman would investigate path to profitability.
-0.01%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is 0.00%. Seth Klarman would investigate cash flow improvement potential.